Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-07-04
2008-09-16
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S247000
Reexamination Certificate
active
07425532
ABSTRACT:
The present invention relates to the use of one inhibitor or of several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity for the induction of the production of TGF-β1 and of the expression of TGF-β1 in and/or on Treg cells and relates to the use for preventing and/or treating autoimmune diseases, allergies, arteriosclerosis and for suppressing graft rejection reactions. The invention furthermore relates to uses, wherein peptide fragments of pathogenic autoantigens or synthetic analogs and/or specific antigenic components of pathogenic microorganisms are used in addition.
REFERENCES:
patent: 2006/0040850 (2006-02-01), Ansorge et al.
patent: 101 00 052 A 1 (2002-07-01), None
patent: 10310599 (1998-11-01), None
patent: 410310599 (1998-11-01), None
patent: WO 91/08760 (1991-06-01), None
patent: WO 95/04533 (1995-02-01), None
patent: WO 96/12737 (1996-05-01), None
patent: WO 01/54707 (2001-08-01), None
patent: WO 01/89569 (2001-11-01), None
Lendeckel et al., “Inhibition of alanyl aminopeptidase induces MAP-kinase p42/ERK2 in the human T cell line KARPAS-299,” Biochem. Biophys. Res. Comm., 1998, 252, 5-9.
Kakuta et al. “Novel specific puromycin-sensitive aminopeptidase inhibitors: 3-(2,6-diethylphenyl)-2,4(1H,3H)-quinazolinedione and N-(2,6-diethylphenyl)-2-amino-4H-3,1-benzoxazin-4-one,” Heterocycles, 2001, 55, 1433, abstract only.
Sharabi et al. “A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta.” PNAS, 2006, 103, 8810-5.
Youn et al. “Metallothionein suppresses collagen-induced arthritis via induction of TGF-beta and down-regulation of proinflammatory mediators.” Clin. Exp. Immunol., 2002, 129, 232-9.
Le et al. “The immunopharmacological properties of transforming growth factor beta.” Int. Immunopharm., 2005, 5, 1771-82.
Ansorge, et al.; Dipeptidyl Peptidase IV/CD26 and Aminopeptidase N/CD13 in Regulation of the Immune Response; In: International Congress Series, 2001, 1218 (Cell-Surface Aminopeptidases: Basic and Clinical Aspects), pp. 85-94.
Ansorge Siegfried
Lendeckel Uwe
Tadje Janine
Bradley Christina Marchetti
Hodgson & Russ LLP
IMTM GmbH
Tsang Cecilia
LandOfFree
Use of alanyl aminopeptidase inhibitors and pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of alanyl aminopeptidase inhibitors and pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of alanyl aminopeptidase inhibitors and pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3975742